Correction: Pediatric Drugs (2024) 26:631–648 10.1007/s40272-024-00656-4
In this article, in Table 1, ‘DTG single” row: The cell entry in the PADO-3 column, which previously read: “DTG + FTC or FTC + TAF” should have read: “DTG + FTC or 3TC + TAF.” The incorrect and the correct versions of Table 1 are shown below.
Incorrect version of Table 1:
Table 1 PADO meetings
The mid-term priorities (3–5 years) are in dark blue, the long-term priorities are in light blue
LPV/r lopinavir/ritonavir, ABC abacavir, 3TC lamivudine, EFV efavirenz, ATV/r atazanavir/ritonavir, NVP nevirapine, DRV/r darunavir/ritonavir, RAL raltegravir, DTG dolutegravir, F/TAF emtricitabine/tenofovir alafenamide, XTC emtricitabine or lamivudine, AZT zidovudine, FTC emtricitabine, DT dispersible tablet, CAB cabotegravir, PNP postnatal prophylaxis
Correct version of Table 1:
Table 1 PADO meetings
The mid-term priorities (3–5 years) are in dark blue, the long-term priorities are in light blue
LPV/r lopinavir/ritonavir, ABC abacavir, 3TC lamivudine, EFV efavirenz, ATV/r atazanavir/ritonavir, NVP nevirapine, DRV/r darunavir/ritonavir, RAL raltegravir, DTG dolutegravir, F/TAF emtricitabine/tenofovir alafenamide, XTC emtricitabine or lamivudine, AZT zidovudine, FTC emtricitabine, DT dispersible tablet, CAB cabotegravir, PNP postnatal prophylaxis
The original article has been corrected.